The active ingredient in aspirin, ASA, is poorly soluble in water. A co-crystal changes that.
© RUB, Marquard

Chemistry Co-crystal improves the water-solubility of ASA

This could benefit patients diagnosed with suspected acute myocardial infarction.

For decades, researchers have been looking for ways to make the active ingredient acetylsalicylic acid (ASA) – the active ingredient of Aspirin – more water-soluble. It’s used not only as pain relief, but also to prevent the formation of life-threatening blood clots in heart attacks and strokes. The faster the drug works, the better. A team from the Inorganic Chemistry Department at Ruhr University Bochum, Germany, headed by Dr. Klaus Merz has now succeeded in combining the active ingredient with an ineffective excipient to form a co-crystal that makes it more water-soluble and thus more effective. Ruhr University Bochum has applied for a European patent for this novel process.

Clever crystal design improves properties

Alongside the development of new active pharmaceutical ingredients, improving the properties of established pharmaceutical products is a specialist area of research. One way to improve properties is through the clever design of crystalline substances known as co-crystals. In addition to the active ingredient, they contain molecules of other substances, so-called co-formers, which are arranged in a well-structured manner in the crystalline material. “Picture these two substances like a married couple: they’re always next to each other, but they aren’t firmly connected,” illustrates Klaus Merz. “If the co-crystal comes into contact with water, the bond dissolves and the active ingredient is released, while the excipient is degraded or excreted.”

When the water solubility of ASA is improved in this way, the active ingredient is of particular interest, because it’s used as a platelet aggregation inhibitor: It promotes blood flow and reduces the risk of thrombosis. In patients with suspected myocardial infarction, ASA is used for immediate treatment. Early administration of ASA reduces mortality by a quarter. “The substance patented here, which contains the active ingredient ASA, is significantly more water-soluble than conventional drugs and ensures that the active ingredient is absorbed more quickly into the bloodstream and can consequently take effect more quickly,” highlights Klaus Merz.

Press contact

Dr. Klaus Merz
Inorganic Chemistry I
Ruhr University Bochum
Germany
Phone: +49 234 32 24187
Cell phone: +49 162 418 53 50
Email: klaus.merz@ruhr-uni-bochum.de

Download high-resolution images
The selected images are downloaded as a ZIP file. The captions and image credits are available in the HTML file after unzipping.
Conditions of use
The images are free to use for members of the press, provided the relevant copyright notice is included. The images may be used solely for press coverage of Ruhr-Universität Bochum that relates solely to the contents of the article that includes the link for the image download. By downloading the images, you receive a simple right of use for one-time reporting. Saving the images for other purposes or further processing of the images that goes beyond adapting them to the respective layout requires an extended right of use. Should you therefore wish to use the photos in any other way, please contact redaktion@ruhr-uni-bochum.de

Published

Wednesday
13 September 2023
9:19 am

By

Meike Drießen (md)

Translated by

Donata Zuber

Share